References
Liu J, Dong Y, Lu C, Wang Y, Peng L, Jiang M, Tang Y, Zhao Q (2017) Meta-analysis of the correlation between vitamin D and lung cancer risk and outcomes. Oncotarget 8(46):81040–81051
Krishnan AV, Trump DL, Johnson CS, Feldman D (2010) The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 39(2):401–418
Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Shoenfeld Y, Lerchbaum E, Llewellyn DJ, Kienreich K, Soni M (2013) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 12(10):976–989
Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE (2016) Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol 34(15):1741–1747
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW (2015) Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 33(13):1482–1490
Bittenberrg JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M et al (2014) Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 32(29):3242–3248
Shah K, Parikh S, Rawal R (2016) Tyrosine kinase inhibitors in Ph+ chronic myeloid leukemia therapy: a review. Asian Pac J Cancer Prev 17(7):3025–3033
Ilander M, Kreutzman A, Mustjoki S (2014) IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia. Oncoimmun 3:e28781
Holick MF, Binkley NC, Bisschoff-Ferrari HA et al (2011) Evalutation, treatment, and prevention of vitamin D deficiency: endocrine society clinical guideline. J Clin Endocrinol Metab 96:1911–1930
Rosen CJ, Abrams SA, Aloia JF et al (2012) IOM committee members respond to endocrine society vitamin D guideline. J Clin Endocrinol Metab 97(4):1146–1152
Schoenmakers I, Goldberg GR, Prentice A (2008) Abundant sunshine and vitamin D deficiency. Br J Nutr 99(6):1171–1173
Saito M, Izumiyama K, Mori A, Irie T, Tanaka M, Morioka M, Saga A, Musashi M, Kato T, Meguro T, Tanino M (2014) Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Rinsho Ketsueki 55(1):130–132 (in Japanese)
Kmira Z, Nesrine BS, Houneida Z, Wafa BF, Aida S, Yosra BY, Monia Z, Sriha B, Abderrahim K (2013) Severe hemorrhagic colitis in a patient with chronic myeloid leukemia in the blastic phase after dasatinib use. World J Gastrointest Pathophysiol 4(3):59–62
Campiotti L, Suter MB, Bolzacchini E, Uccella S, Grandi AM, Guasti L (2017) Colitis and chronic bleeding in patients treated with dasatinib. J Cancer Res Ther 5(5):32–33
Funding
No funding source financed this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
The study was approved by local institution.
Informed consent
Every patients signed informed consensus.
Rights and permissions
About this article
Cite this article
Campiotti, L., Bolzacchini, E., Sutter, M.B. et al. Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia. Intern Emerg Med 13, 1337–1339 (2018). https://doi.org/10.1007/s11739-018-1957-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-018-1957-0